Greatmark Investment Partners Inc. grew its stake in Johnson & Johnson (NYSE:JNJ) by 1.7% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 74,296 shares of the company’s stock after buying an additional 1,217 shares during the quarter. Johnson & Johnson makes up 3.1% of Greatmark Investment Partners Inc.’s portfolio, making the stock its 9th biggest holding. Greatmark Investment Partners Inc.’s holdings in Johnson & Johnson were worth $10,348,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other institutional investors and hedge funds also recently modified their holdings of JNJ. Fisher Asset Management LLC grew its holdings in Johnson & Johnson by 2.6% during the 2nd quarter. Fisher Asset Management LLC now owns 11,841,121 shares of the company’s stock valued at $1,649,231,000 after buying an additional 301,124 shares in the last quarter. Clearbridge Investments LLC grew its holdings in Johnson & Johnson by 0.5% during the 1st quarter. Clearbridge Investments LLC now owns 9,628,443 shares of the company’s stock valued at $1,345,960,000 after buying an additional 48,582 shares in the last quarter. Nordea Investment Management AB grew its holdings in Johnson & Johnson by 14.2% during the 1st quarter. Nordea Investment Management AB now owns 8,709,414 shares of the company’s stock valued at $1,217,494,000 after buying an additional 1,079,751 shares in the last quarter. Thoroughbred Financial Services LLC grew its holdings in Johnson & Johnson by 14,147.0% during the 2nd quarter. Thoroughbred Financial Services LLC now owns 4,014,247 shares of the company’s stock valued at $401,425,000 after buying an additional 3,986,071 shares in the last quarter. Finally, Swedbank grew its holdings in Johnson & Johnson by 5.5% during the 4th quarter. Swedbank now owns 4,001,754 shares of the company’s stock valued at $509,303,000 after buying an additional 209,665 shares in the last quarter. Institutional investors and hedge funds own 67.23% of the company’s stock.
In other Johnson & Johnson news, Director Marillyn A. Hewson purchased 3,000 shares of the firm’s stock in a transaction that occurred on Tuesday, June 11th. The stock was purchased at an average cost of $139.68 per share, with a total value of $419,040.00. Following the purchase, the director now owns 3,000 shares of the company’s stock, valued at $419,040. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.23% of the stock is currently owned by company insiders.
Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Tuesday, July 16th. The company reported $2.58 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $2.42 by $0.16. Johnson & Johnson had a return on equity of 38.63% and a net margin of 20.08%. The firm had revenue of $20.56 billion during the quarter, compared to analyst estimates of $20.39 billion. During the same period last year, the company earned $2.10 EPS. Johnson & Johnson’s quarterly revenue was down 1.3% compared to the same quarter last year. As a group, sell-side analysts forecast that Johnson & Johnson will post 8.6 EPS for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 10th. Investors of record on Tuesday, August 27th will be paid a dividend of $0.95 per share. This represents a $3.80 dividend on an annualized basis and a dividend yield of 2.96%. The ex-dividend date is Monday, August 26th. Johnson & Johnson’s dividend payout ratio is currently 46.45%.
Several research firms have weighed in on JNJ. Barclays began coverage on Johnson & Johnson in a report on Friday, June 21st. They set a “hold” rating and a $140.00 price target for the company. Goldman Sachs Group set a $169.00 price objective on Johnson & Johnson and gave the company a “buy” rating in a research note on Tuesday. Morgan Stanley reaffirmed an “equal weight” rating and issued a $145.00 price objective on shares of Johnson & Johnson in a research note on Tuesday. Wells Fargo & Co reaffirmed an “outperform” rating and issued a $157.00 price objective (up from $152.00) on shares of Johnson & Johnson in a research note on Monday, May 6th. Finally, Royal Bank of Canada reaffirmed a “buy” rating on shares of Johnson & Johnson in a research note on Tuesday, July 16th. Five analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $150.60.
Johnson & Johnson Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Further Reading: What is cost of equity?
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.